PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
August 24, 2025Open Access

AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence

View Full Paper
Ask AI
Bookmark
Share

Authors

WNWaqas NawazIslamic University of MadinahAIAwais Ullah IhsanUniversité de SherbrookeMRMuhammad RehanAdventHealth Sebring

Discussion

Loading...

Member takes

Overview

AAV-based CAR T therapy reduces HIV viral load in CD4 cells, indicating a potential cure is achievable.

Key Points

  • AAVCD4CAR T cells significantly reduce viral p24 levels in infected human samples, showing potential against HIV.
  • In a humanized mouse model, treated mice maintained CD4+ T cell counts while suppressing plasma viremia compared to controls.
  • The methodology involved AAV-mediated CAR delivery, promoting safety and persistence in targeting HIV-infected cells.
  • The findings highlight the effectiveness of AAVCD4CAR in combating latent HIV reservoirs and support its future development.

Cite This Study

Nawaz et al. (2025) studied this question.

synapsesocial.com/papers/68af5d69ad7bf08b1eae0c1dhttps://doi.org/10.1101/2025.08.22.671679
View Full Paper
Ask AI
Bookmark
Share